Stanford pain researchers say we can curb the prescription opioid crisis, while treating pain, by using a variety of tactics.
Using human embryonic stem cells to study nicotine's effect in development shows defects in cellular communication and longevity, say Stanford scientists.
Alvin Roth, a Nobel laureate and Stanford faculty member, explains how the economic concept of repugnant markets applies to heroin in the United States.
Small trial conducted by Stanford researchers links activity in the brain's reward processing system with drug relapse in patient cohort.
In this commentary, Stanford tobacco expert Robert Jackler adds context to the recent decision by JUUL to stop direct social media in the U.S.
During a talk at Stanford, journalist and author Barry Meier discussed his nearly two-decade long investigation into OxyContin and Purdue Pharma.
A recent NOVA episode focused on our country's addiction problem and highlighted the work of numerous researchers.
A team of economists have examined the importance of location and opioid prevalence to help tease out the relative importance of supply in the epidemic.
New Stanford research shows alarming trends in teens' use of a popular vaping device, suggesting they need better education about its addictive potential.
Following surgery, the risk of overdose from opioids is highest during the first month. Taking both short- and long-acting opioids also boosts the risk.
Ketamine, a promising new treatment for depression, works through the brain's opioid system, Stanford study finds, defying long held beliefs.
Even substantial efforts in reducing opioid addiction, preventing overdoses and providing addiction treatment won't curb the crisis any time soon.
Stanford researchers examine the use of deep brain stimulation therapy to treat alcohol use disorders and reduce relapse rates.
In a JAMA opinion piece, Gary Peltz and Tom Sudhof argue for policymakers and health leaders to combat opioid addictions early.
Researchers have studied the complex chemical composition of e-cigarette vapors to predict their health impacts on users and those around them.
Years into the opioid epidemic, Stanford psychiatrist and addiction researcher Anna Lembke cites signs of slow improvement and comments on benzodiazepines.
